Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Author information

1
1Memorial Sloan Kettering Cancer Center.
2
2Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
3
3Massachusetts General Hospital Cancer Center.
4
4Stanford Cancer Institute.
5
5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
6
6Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
7
7University of Wisconsin Carbone Cancer Center.
8
8Moffitt Cancer Center.
9
9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
10
10The University of Texas MD Anderson Cancer Center.
11
11Huntsman Cancer Institute at the University of Utah.
12
12Mayo Clinic Cancer Center.
13
13Roswell Park Comprehensive Cancer Center.
14
14University of Michigan Rogel Cancer Center.
15
15Duke Cancer Institute.
16
16Fox Chase Cancer Center.
17
17Consultant.
18
18Dana-Farber/Brigham and Women's Cancer Center.
19
19O'Neal Comprehensive Cancer Center at UAB.
20
20City of Hope National Medical Center.
21
21University of Colorado Cancer Center.
22
22Vanderbilt-Ingram Cancer Center.
23
23UC San Diego Moores Cancer Center.
24
24Yale Cancer Center/Smilow Cancer Hospital.
25
25University of Washington/Seattle Cancer Care Alliance.
26
26The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
27
27Fred & Pamela Buffett Cancer Center; and.
28
28National Comprehensive Cancer Network.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

PMID:
31200358
DOI:
10.6004/jnccn.2019.0029

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center